<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330040</url>
  </required_header>
  <id_info>
    <org_study_id>D0816R00025</org_study_id>
    <nct_id>NCT04330040</nct_id>
  </id_info>
  <brief_title>Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer</brief_title>
  <acronym>SOLI</acronym>
  <official_title>A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with
      Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following
      Platinum based Chemotherapy and Metastatic Breast Cancer with germline BRCA (BReast CAncer
      gene) 1/2 Mutation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with
      Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following
      Platinum based Chemotherapy and Metastatic Breast Cancer with germline BRCA(BReast CAncer
      gene)1/2 Mutation As per recommendation from DCGI(Drug Controller general of of India), the
      current phase-IV study is planned with the aim to assess the safety in Indian subjects
      receiving olaparib as per the approved label indications in India in accordance with the
      requirements of the Health Authorities of India. This study attempts to descriptively
      elucidate the safety of Olaparib in Indian subjects receiving olaparib as per the Indian
      regulatory approved indications in India. The data obtained from the present study will help
      to understand the safety profile of olaparib in Indian patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A Prospective, Multicentre, Phase-IV Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety of olaparib in Indian subjects</measure>
    <time_frame>6 Months</time_frame>
    <description>Number, frequency and proportion of subjects with adverse events (AEs) and serious adverse events (SAEs).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: Olaparib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated, written informed consent form prior to any mandatory
             study specific procedures..

          2. Female Subjects with â‰¥ 18 years of age

          3. Subjects receiving olaparib for the following indications in ovarian cancer:

             for the maintenance treatment of adult subjects with recurrent epithelial ovarian,
             fallopian tube or primary peritoneal cancer, who are in a complete or partial response
             to platinum-based chemotherapy

          4. Subjects receiving olaparib for the following indication in breast cancer:

        in subjects with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic
        breast cancer who have previously been treated with chemotherapy in the neoadjuvant,
        adjuvant or metastatic setting. Subjects with HR-positive breast cancer should have been
        treated with a prior endocrine therapy or be considered inappropriate for endocrine
        treatment

        Exclusion Criteria:

          1. Patients with either the history of hypersensitivity to excipients of the study drug
             or to drugs with a similar chemical structure or class to the study drug.

          2. pregnant and/or lactating women.

          3. Patients with a previously or currently diagnosed MDS/ AML or pneumonitis.

          4. Patients who have not recovered sufficiently from prior surgery or anticancer
             treatment.

          5. Patients who have known history of hepatitis B or hepatitis C

          6. Patients with active infection such as TB.

          7. Participation in another clinical study with a study drug administered in the last 3
             months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BLK Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Agarwal</last_name>
      <phone>9971611311</phone>
      <email>deepaliamit@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joydeep Ghosh</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700160</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TATA Medical Center Trust</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer; Breast Cancer, Olaparib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

